This technology is a gene signature of early bladder cancer that is associated with adverse disease outcome and can be used as a clinical prognostic.
The progression of non-muscle invasive bladder cancer (NMIBC) to muscle invasive bladder cancer (MIBC) is associated with significantly decreased survival rates and requires early intervention. There is currently no tool to predict whether a patient is likely to progress from NMIBC to MIBC. Identifying high-risk bladder cancer patients is essential to determine treatment options and to prevent disease progression.
This technology provides a signature of early bladder cancer comprised of 28 genes that are conserved and upregulated in the subset of patients that have NMIBC and later develop MIBC. The pre-invasive phenotype of basal bladder cells identifies molecular pathways associated with bladder tumorigenesis and adverse disease outcomes. The gene signature can be used as a prognostic that will enable clinicians to determine the best course of action for an individual patient and prevent cancer progression.
This technology has been validated with mouse models and human bladder cancers.
Patent Pending
IR CU21285
Licensing Contact: Joan Martinez